FibroGen Inc expected to post a loss of 30 cents a share - Earnings Preview

Kyntra Bio

08/11/2024 21:40

* FibroGen Inc  FGEN.OQ   FGEN.O  is expected to show a fall
in
quarterly revenue when it reports  results on November 12 for
the period ending September 30 2024
    * The San Francisco California-based  company is expected to
report a 13.4% decrease in revenue to $34.763 million from
$40.13 million a year ago, according to the mean estimate from 2
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for FibroGen Inc is for a
loss
of 30 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for FibroGen
Inc is
$0.60​, above​ its last closing price of $0.31. ​​​

This summary was machine generated November 8 at 21:39 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)